Savara Inc (SVRA)

NASDAQ
Currency in USD
2.3750
+0.1050(+4.63%)
Closed·
After Hours
2.3700-0.0050(-0.2105%)
·
SVRA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SVRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.25002.5000
52 wk Range
1.89005.1100
Key Statistics
Edit
Prev. Close
2.27
Open
2.3
Day's Range
2.25-2.5
52 wk Range
1.89-5.11
Volume
1.32M
Average Vol. (3m)
1.51M
1-Year Change
-50.33%
Book Value / Share
0.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SVRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.0625
Upside
+197.37%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Savara Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Savara Inc Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.

Savara Inc SWOT Analysis


Analyst Projections
Analyst price targets range from $2 to $16 per share, with Wells Fargo and JMP Securities maintaining bullish outlooks of $7 and $9, respectively
Financial Outlook
Delve into Savara's financial strategy, including $173M cash reserves and a $200M debt agreement, supporting operations through potential 2026 product launch
Market Opportunity
Explore the expanded addressable market for aPAP treatment, with over 7,000 potential patients in the U.S. and projected peak sales exceeding $1 billion
Breakthrough Therapy
Savara's Molbreevi, a potential first-in-class treatment for aPAP, completes BLA submission with promising Phase 3 data and Breakthrough Therapy designation
Read full SWOT analysis

Compare SVRA to Peers and Sector

Metrics to compare
SVRA
Peers
Sector
Relationship
P/E Ratio
−4.9x−4.9x−0.5x
PEG Ratio
0.140.020.00
Price / Book
3.4x2.6x2.6x
Price / LTM Sales
-28.1x3.1x
Upside (Analyst Target)
230.4%145.1%47.8%
Fair Value Upside
Unlock7.1%6.9%Unlock

Analyst Ratings

6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 7.0625
(+197.37% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-0.12 / -0.10
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SVRA Income Statement

People Also Watch

16.26
COLD
-1.03%
2.370
ACHV
+4.87%
3.890
LAES
-2.02%
17.53
SLP
+0.11%
3.20
RCKT
+8.11%

FAQ

What Is the Savara (SVRA) Stock Price Today?

The Savara stock price today is 2.38

What Stock Exchange Does Savara Trade On?

Savara is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Savara?

The stock symbol for Savara is "SVRA."

What Is the Savara Market Cap?

As of today, Savara market cap is 497.23M.

What Is Savara's Earnings Per Share (TTM)?

The Savara EPS (TTM) is -0.49.

When Is the Next Savara Earnings Date?

Savara will release its next earnings report on Aug 07, 2025.

From a Technical Analysis Perspective, Is SVRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Savara Stock Split?

Savara has split 2 times.

How Many Employees Does Savara Have?

Savara has 59 employees.

What is the current trading status of Savara (SVRA)?

As of Jul 10, 2025, Savara (SVRA) is trading at a price of 2.38, with a previous close of 2.27. The stock has fluctuated within a day range of 2.25 to 2.50, while its 52-week range spans from 1.89 to 5.11.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.